UBS Maintains Neutral on GoodRx Holdings, Lowers Price Target to $4
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and lowers the price target from $4.25 to $4.
UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and lowers the price target from $4.25 to $4.